By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today disclosed the final terms of its proposed acquisition of RedPath.

Under the terms, which are up for a vote by shareholders, ExonHit will pay $12.5 million in cash and $10 million in stock. ExonHIt will issue 2,834,412 new shares of its stock, which represents 7.95 percent of the 35,656,294 ordinary shares that will be outstanding after the close of the purchase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.